Oct 4 Reuters - The Canadian drugmaker GlaxoSmithKline PLC said on Monday that it signed a deal to supply 10,000 doses of its COVID 19 monoclonal antibody therapy to London.
With the emergence of variants of concern across the country, in particular the Delta variant, new therapies like sotrovimab are important to treating disease in its early stages, said Ranya El Masri, head of government affairs and market access for GSK Canada.
The drug, sotrovimab, developed in partnership with Vir Biotechnology Inc. in July was approved by Canada to treat mild to moderate COVID - 19 patients, above 12 years of age, who are at high risk for progressing to hospitalization or death.
The agreement allows Canada's provincial and territorial healthcare systems to purchase additional doses from this month and provides an option for the Canadian government to gain access to Sotrovimab next year, based on its needs, GSK said.
Sotrovimab has also been approved for treating COVID--19 in the United States, Japan and the European Union, among others.